WEKO3
アイテム
シスプラチン・リピオドールの経肝動脈および経門脈併用投与によるラット肝癌への影響
https://kindai.repo.nii.ac.jp/records/2002622
https://kindai.repo.nii.ac.jp/records/200262270143aff-30a9-42d5-a6c7-91624a4eb218
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
AN00063584-19910625-0203.pdf (2.2 MB)
|
|
| アイテムタイプ | ☆紀要論文 / Departmental Bulletin Paper(1) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2025-03-24 | |||||||||
| タイトル | ||||||||||
| タイトル | シスプラチン・リピオドールの経肝動脈および経門脈併用投与によるラット肝癌への影響 | |||||||||
| 言語 | ja | |||||||||
| タイトル | ||||||||||
| タイトル | The effects of hepatic arterial and portal venous administration of Lipiodol-suspended cisplatinon on rat hepatic carcinoma | |||||||||
| 言語 | en | |||||||||
| 著者 |
小野, 幸彦
× 小野, 幸彦
|
|||||||||
| 言語 | ||||||||||
| 言語 | jpn | |||||||||
| キーワード | ||||||||||
| 主題 | cisplatin, Lipiodol, 3'-Me-DAB-induced hepatic carcinomatous rats, hepatic arterial administration, combining hepatic arterial plus portal venous administration | |||||||||
| 資源タイプ | ||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||
| 資源タイプ | departmental bulletin paper | |||||||||
| 版 | ||||||||||
| 出版タイプ | AM | |||||||||
| 出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||||||
| 出版者 名前 | ||||||||||
| 出版者 | 近畿大学医学会 | |||||||||
| 言語 | ja | |||||||||
| 書誌情報 |
ja : 近畿大学医学雑誌 en : Medical Journal of Kinki University 巻 16, 号 2, p. 203-217, 発行日 1991-06-25 |
|||||||||
| ISSN | ||||||||||
| 収録物識別子タイプ | PISSN | |||||||||
| 収録物識別子 | 03858367 | |||||||||
| 内容記述 | ||||||||||
| 内容記述タイプ | Abstract | |||||||||
| 内容記述 | To develop a new treatment for hepatic carcinoma, cisplatin (cis-diamminedichloroplatinum II, CDDP), suspended in an oily contrast medium, Lipiodol (LPD), was administered via both the hepatic artery and the portal vein, as well via the hepatic artery alone, into rats with 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)-induced hepatic carcinoma. Based upon the results of a preliminary experiment using normal rats, the volume was set at 0.1ml per blood vessel (10mg of fine ground CDDP suspended in 1ml of LPD). Prior to the start of the experiment, contrast medium was injected via the hepatic artery or the portal vein into rats with 3'-Me-DAB-induced hepatic carcinoma. Low kilovoltage radiography and tetraline cleared specimens showed that the contrast medium sent through the hepatic artery accumulated selectively in the central area of the tumor nests, while that sent through the portal vein accumulated selectively in the peripheral area. Tumor growth rates in the hepatic artery plus portal vein group (H+P group), compared to the hepatic artery group (H group), were lower 5days after administration and tended to be even lower on the 21st day. Platinum concentrations in the liver were significantly higher in the carcinoma nests than in the other non-tumorous areas. In the H+P group carcinoma nests, the platinum concentrations were higher than in the H group carcinoma nests. Histologically, carcinoma cells in the peripheral areas of the carcinoma nest, as well as those in the central areas, were moderately degenerated and necrotic. Tumor-disappearing rates (necrosis rates+fibrotic rates) in the H+P group were 65.2% on the 5th day after administration and 69.6% on the 21st day. Both values were significantly higher than those in the H group. Necrosis and degeneration were not found in the non-tumorous areas of the liver 21days after administration. Body weight in the H+P group, as well as the H group, decreased 5days following administration, but some of the animals had recovered to their original weight by the 21st day. These results indicate that this new method of combining hepatic arterial plus portal venous administration of CDDP+LPD suspension is very effective in the treatment of hepatic carcinoma. | |||||||||
| 言語 | en | |||||||||
| 内容記述 | ||||||||||
| 内容記述タイプ | Other | |||||||||
| 内容記述 | 本文データはCiNiiから複製したものである。 | |||||||||
| 言語 | ja | |||||||||
